Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of GDC-0853: Formulation, Food, and Rabeprazole Effects
NCT03290703Phase 1Completed
- Sponsor
- Genentech
- Start
- Apr 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fenebrutinib in multiple sclerosis (MS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and 1 more (3 arms), sponsored by Genentech. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Observed Plasma Concentration and 8 more. Started Apr 2017; status: completed.
02
Drugs
fenebrutinib
03
Conditions
multiple sclerosis (MS)rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT03290703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03290703.